1

Akeso’s AK117‑302 Phase 3 Trial Enrolls First Patient (Oct 2024)

News Discuss 
Akeso Biopharma began enrollment for its multicenter AK117‑302 Phase 3 study in October 2024, evaluating their antibody in head & neck squamous cell carcinoma . https://www.datamintelligence.com/research-report/head-and-neck-cancer-pipeline-insights

Comments

    No HTML

    HTML is disabled


Who Upvoted this Story